Shares in Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) jumped 19% on Monday after the biotech announced a manufacturing partnership to advance its experimental CAR-T therapy for acute myeloid leukaemia.
The London-listed group said it would work with Made Scientific, a US-based contract manufacturer specialising in cell therapies, to scale up production of HG-CT-1.
The therapy is in early-stage clinical trials for adults with relapsed or treatment-resistant forms of the blood cancer.
Made Scientific will handle technology transfer and manufacturing at its facilities in New Jersey, which are equipped for both clinical and potential commercial supply.
The agreement is expected to accelerate Hemogenyx’s Phase I trial and could support the inclusion of paediatric patients in future cohorts.
Vladislav Sandler, chief executive, said Made Scientific’s expertise would be “instrumental in driving the continued progress of this potentially breakthrough therapy”.
Early trial data have shown encouraging safety and efficacy signals, the company added.
The shares rose 142p to 900p.